Evidence-based diagnosis and thrombolytic treatment of cardiac arrest or periarrest due to suspected pulmonary embolism
Autor: | Hardin Pantle, Paul Huiras, Jill K. Logan, Leah Bright, Edward S. Bessman |
---|---|
Rok vydání: | 2014 |
Předmět: |
medicine.medical_specialty
Streptokinase medicine.medical_treatment Tenecteplase Fibrinolytic Agents Humans Medicine Thrombolytic Agent Thrombolytic Therapy Intensive care medicine business.industry Advanced cardiac life support General Medicine Thrombolysis medicine.disease Urokinase-Type Plasminogen Activator Recombinant Proteins Heart Arrest Pulmonary embolism Tissue Plasminogen Activator Emergency Medicine Pulmonary Embolism business Complication Fibrinolytic agent medicine.drug |
Zdroj: | The American Journal of Emergency Medicine. 32:789-796 |
ISSN: | 0735-6757 |
DOI: | 10.1016/j.ajem.2014.04.032 |
Popis: | When a previously healthy adult experiences atraumatic cardiac arrest, providers must quickly identify the etiology and implement potentially lifesaving interventions such as advanced cardiac life support. A subset of these patients develop cardiac arrest or periarrest due to pulmonary embolism (PE). For these patients, an early, presumptive diagnosis of PE is critical in this patient population because administration of thrombolytic therapy may significantly improve outcomes. This article reviews thrombolysis as a potential treatment option for patients in cardiac arrest or periarrest due to presumed PE, identifies features associated with a high incidence of PE, evaluates thrombolytic agents, and systemically reviews trials evaluating thrombolytics in cardiac arrest or periarrest. Despite potentially improved outcomes with thrombolytic therapy, this intervention is not without risks. Patients exposed to thrombolytics may experience major bleeding events, with the most devastating complication usually being intracranial hemorrhage. To optimize the risk-benefit ratio of thrombolytics for treatment of cardiac arrest due to PE, the clinician must correctly identify patients with a high likelihood of PE and must also select an appropriate thrombolytic agent and dosing protocol. |
Databáze: | OpenAIRE |
Externí odkaz: |